Author:
Balogun Fatai Oladunni,Singh Karishma,Rampadarath Athika,Akoonjee Ayesha,Naidoo Kayleen,Sabiu Saheed
Abstract
Abstract
Purpose
The therapeutic use of oral hypoglycaemic agents in the management of type-2 diabetes mellitus (T2DM) is without adverse effects; thus, calls for alternative and novel candidates from natural products in medicinal plants.
Method
The study explored molecular docking and molecular dynamics (MD) simulation approaches to identify key antidiabetic metabolites from Crescentia cujete.
Results
Molecular docking results identified four and/or five best compounds against each target enzyme (alpha-glucosidase, dipeptidyl peptidase-IV, aldose reductase, and protein tyrosine phosphatase-1B (PTP-1B)) implicated in diabetes. The resulting complexes (except against PTP-1B) had higher docking scores above respective standards (acarbose, Diprotin A, ranirestat). The MD simulation results revealed compounds such as benzoic acid (-48.414 kcal/mol) and phytol (-45.112 kcal/mol) as well as chlorogenic acid (-42.978 kcal/mol) and naringenin (-31.292 kcal/mol) had higher binding affinities than the standards [acarbose (-28.248 kcal/mol), ranirestat (-21.042 kcal/mol)] against alpha-glucosidase and aldose reductase, respectively while Diprotin A (-45.112 kcal/mol) and ursolic acid (-18.740 kcal/mol) presented superior binding affinities than the compounds [luteolin (-41.957 kcal/mol and naringenin (-16.518 kcal/mol)] against DPP-IV and PTP-1B respectively.
Conclusion
While isoflavone (alpha-glucosidase), xylocaine (DPP-IV), luteolin (aldose reductase,) and chlorogenic acid (PTP-1B) were affirmed as the best inhibitors of respective enzyme targets, luteolin, and chlorogenic acid may be suggested and proposed as probable candidates against T2DM and related retinopathy complication based on their structural stability, compactness and affinity for three (DPP-IV, aldose reductase, and PTP-1B) of the four targets investigated. Further studies are warranted in vitro and in vivo on the antihyperglycaemic effects of these drug candidates.
Funder
Durban University of Technology
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference78 articles.
1. Sapra A, Bhandari P, Diabetes Mellitus. [Updated 2021 Sep 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK551501/. Accessed 20 Jan 2022.
2. WHO, Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed Dec 13 2021.
3. Westman EC. Type 2 diabetes Mellitus: a pathophysiologic perspective. Front Nutr. 2021;8.https://doi=10.3389/fnut.2021.707371.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. 2011.
5. Cho NH, Shaw JE, Karuranga S. IDF diabetes atlas: global estimates of diabetes prevalence of for 2017 and projections for 2045. J Diab. 2018;138:271–28.